Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 14/20 | 0.51 |
| ▸ | MMP9 | P14780 | 5/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 4/20 | 0.48 |
| ▸ | MMP1 | P03956 | 3/20 | 0.48 |
| ▸ | MMP13 | P45452 | 3/20 | 0.48 |
| ▸ | MMP7 | P09237 | 2/20 | 0.48 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7072473 | 1.00 | MMP2 (0.51) | MMP2MMP9CA12CA1CA2 | |
| SCHEMBL13254806 | 0.83 | MMP2 (0.54) | MMP2MMP9CA12CA1CA2 | |
| SCHEMBL13282810 | 0.83 | MMP2 (0.54) | MMP2MMP9CA12CA1CA2 | |
| SCHEMBL10904756 | 0.80 | ALDH1A1 (0.61) | MMP2MMP9CA12CA1CA2 | |
| SCHEMBL10904755 | 0.80 | ALDH1A1 (0.61) | MMP2MMP9CA12CA1CA2 | |
| SCHEMBL5503977 | 0.76 | MMP2 (0.66) | MMP2MMP9CA12CA1CA2 | |
| SCHEMBL29508846 | 0.76 | LMNA (0.66) | ALDH1A1KMT2A | |
| SCHEMBL23630457 | 0.75 | POLB (0.61) | MMP2POLBANPEPALDH1A1KMT2A | |
| SCHEMBL3832846 | 0.75 | POLB (0.61) | MMP2POLBANPEPALDH1A1KMT2A | |
| SCHEMBL6097783 | 0.75 | POLB (0.61) | MMP2POLBANPEPALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6586602-B2 | CD antigen antagonists such as N-(methanesulfonyl)-L-prolyl-L-phenylalanine and prodrugs used as antiinflammatory agents | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-07-01 | — | — | US | disclosed |
| US-20030065193-A1 | Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-04-03 | — | — | US | disclosed |
| US-6362341-B1 | ANTIINFLAMMATORY AGENTS | ATHENA NEUROSCIENCES, INC. | 2002-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065193-A1 | Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, ITGB4 | MMP2 472/4885MMP9 498/4885CA12 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.